1 active not recruiting, 1 completed, 1 not yet recruiting, 1 unknown. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Active not recruiting 1, Completed 1, Not yet recruiting 1, Unknown 1 |
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis Ruxolitinib - Myelofibrosis | Phase 4 | Unknown | Qilu Hospital of Shandong University | 87 | 2022-06-10 | 2022-07-07 |
| CINC424A2X01B Rollover Protocol ruxolitinib, panobinostat - Primary Myelofibrosis, Polycythemia Vera | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 279 | 2015-03-05 | 2026-10-19 |
| Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) INC424 - Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF) | Phase 4 | Completed | Novartis Pharmaceuticals | 48 | 2012-05-01 | 2015-03-03 |
Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1) · Bronchiolitis Obliterans Syndrome (1) · Graft vs Host Disease (1) · Hemorrhagic Disorders (1) · Leukemia, Myeloid, Acute (1) · Myeloproliferative Disorders (1) · Polycythemia (1) · Polycythemia Vera (1) · Thalassemia (1) · Thrombocythemia, Essential (1) · Thrombocytosis (1)
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Bone Marrow Diseases (3) · Myeloproliferative Disorders (3) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Bone Marrow Neoplasms (1) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchitis (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hematologic Neoplasms (1)
ruxolitinib (4) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (1) · Panobinostat (1)
Novartis Pharmaceuticals (2) · Qilu Hospital of Shandong University (1) · SWOG Cancer Research Network (1)
China (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Chile (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Israel (1) · Italy (1) · Japan (1) · Lebanon (1)
2014 (1)